Abstract Following arterial occlusion, blood vessels respond by forming a new network of functional capillaries (angiogenesis), by reorganizing preexisting capillaries through the recruitment of smooth muscle cells to generate new arteries (arteriogenesis) and by growing and remodeling preexisting collateral arterioles into physiologically relevant arteries (collateral development). All these processes result in the recovery of organ perfusion. The importance of endoglin in post-occlusion reperfusion is sustained by several observations: (1) endoglin expression is increased in vessels showing active angiogenesis/remodeling; (2) genetic endoglin haploinsufficiency in humans causes deficient angiogenesis; and (3) the reduction of endoglin expression by gene disruption or the administration of endoglin-neutralizing antibodies reduces angiogenesis and revascularization. However, the precise role of endoglin in the several processes associated with revascularization has not been completely elucidated and, in some cases, the function ascribed to endoglin by different authors is controversial. The purpose of this review is to organize in a critical way the information available for the role of endoglin in several phenomena (angiogenesis, arteriogenesis and collateral development) associated with post-ischemic revascularization.
Introduction
Adult mammals have developed a set of physiological mechanisms that regulate the supply of nutrients and oxygen to tissues according to their requirements. When an organ changes its metabolism in an acute way, blood flow along arteries, arterioles and capillaries can be controlled, depending on the metabolic requirements of this organ, to maintain a balance between the oxygen and nutrient requirements, the removal of waste products and the blood flow supply. Acute blood flow regulation is managed by adjusting the contraction or relaxation of smooth muscle fibers in the walls of arterioles. However, when an organ or tissue suffers a long-term lack of adequate blood supply (ischemia), some other mechanisms are activated to correct this deficiency. Ischemia comprises not only an insufficiency of oxygen but also a reduced availability of nutrients and an inadequate removal of metabolites. The response to ischemic situations includes a coordinated set of processes: (1) ''de novo'' formation of a network of functional capillaries by budding off of endothelial cells (ECs) from the walls of preexisting capillaries (angiogenesis), (2) transformation of preexisting capillaries in conductance arteries and veins (arteriogenesis) and (3) growth and remodeling of preexisting low flow collateral arterioles that connect main arteries to physiologically relevant arteries (collateral development) [1] . This last process is also called arteriogenesis by several authors [2] . The contribution of each of these processes to revascularization after arterial obstruction depends on the organ perfused and the velocity of the arterial occlusion (acute or progressive).
During angiogenesis, preexisting ECs perform highly orchestrated morphogenic events that include basement membrane degradation, EC sprouting and branching, vessel lumen formation, vessel anastomosis and maturation, and mural cell recruitment, resulting in a new vascular network that provides blood to the hypoxic tissue [3, 4] .
A different strategy to generate adequate blood flow for the metabolic demand of the tissue after ischemia is vascular remodeling, including arteriogenesis and collateral growth or development. Despite the considerable terminological confusion that has even stimulated the writing of specific reviews regarding the nomenclature used [5] , there is an unambiguous difference between arteriogenesis and collateral growth: arteriogenesis is the appearance of new arteriolar structures from preexisting capillaries, whereas collateral growth is the development and remodeling (anatomic increase in lumen area and wall thickness) of preexisting arterio-arterial anastomoses to form functional conducting arteries that significantly contribute to tissue perfusion [1] . During the arteriogenesis process, the persistent increased oxygen demand by the ischemic organ induces arteriolar vasodilatation and increased blood flow in downstream vessels. Consequently, increased shear stress induces the maturation of capillaries toward arteries. In this manner, preexisting EC channels become covered by pericytes and vascular smooth muscle cells (VSMCs), which provide stability and control of the perfusion of newly formed arteries. During the collateral growth process, upon occlusion of an artery, the blood flow is redirected into preexisting arterio-arterial anastomoses (collateral vessels) due to the sudden pressure gradient between the high pressure in pre-occlusive regions and the low pressure in the post-occlusive areas that are connected by these collaterals. Thus, these arteries are exposed to increased mechanical forces such as pulsatile fluid shear stress [6] . As a consequence of the increased shear stress, the endothelium of the collateral arteriolar connections is activated, resulting in increased release of nitric oxide (NO), vascular endothelial growth factor (VEGF) and monocyte-attracting proteins such as monocyte chemoattractant protein-1 (MCP-1), as well as an upregulation of adhesion molecules (VCAM-1, ICAM-1, among others). Upon adherence and extravasation, monocytes promote vascular wall development by supplying growth factors and cytokines such as granulocyte-monocyte colony-stimulating factor (GM-CSF) or transforming growth factor-b1 (TGF-b1) [7] [8] [9] [10] . All these mechanisms are described in detail later in this review.
It has been reported that angiogenic processes take place mainly in the microvascular circulation, whereas the macrovascular endothelium mainly drives arteriogenesis and vascular remodeling. While both have common signaling routes and responses, cell-by-cell analysis shows differential gene expression patterns, suggesting the presence of different highly regulated processes [11] .
Inadequate angiogenesis or arteriogenesis is responsible for several types of diseases (4-6): (1) pathologies with excessive angiogenesis/vascular remodeling including hemangiomas, psoriasis, Kaposi's sarcoma, ocular neovascularization and retinopathy of prematurity, rheumatoid arthritis, endometriosis, atherosclerosis and, the most studied, tumor growth and metastasis; (2) pathologies with poor angiogenesis/vascular remodeling, which include myocardial ischemia, peripheral limb ischemia, cerebral ischemia, delayed wound healing and impaired ulcer healing; and (3) pathologies with defective angiogenesis/vascular remodeling, in which the number of formed vessels is normal, but their structure and cellular composition is abnormal, such as arteriovenous malformations, telangiectasias or even tumor vessels, in which angiogenesis is not only excessive but also defective.
As described above, ECs play a main role in both angiogenic and vascular remodeling processes, and many endothelium-related proteins and soluble factors are also involved in this process. In this context, endoglin (CD105), a co-receptor for several members of the TGF-b family expressed mainly in ECs, has been shown to be essential for the correct course of angiogenic processes [12] [13] [14] . Endoglin expression is enhanced in endothelium during active angiogenesis, in both non-tumor and tumor tissues [15, 16] , and endoglin expression specifically rises at the angiogenic edge where vessel sprouting occurs [17] . A lack of endoglin or defective endoglin function results in impaired angiogenesis, revascularization and tumor growth [18] [19] [20] [21] [22] . Moreover, endoglin is used as a biomarker for a poor prognosis in several cancers [23, 24] , and endoglinneutralizing antibodies have demonstrated anti-tumor angiogenesis properties, as recently reviewed [25, 26] . Additionally, a new role for endoglin in integrin-mediated angiogenic and vascular remodeling processes can be suggested in light of the recent discovery that endoglin is involved in the regulation of leukocyte recruitment [27] and in integrin-dependent cell adhesion processes, including pericyte attachment to ECs [28] . These data suggest that endoglin is a potential target for the regulation of defective or excessive angiogenesis. However, the mechanisms by which endoglin contributes to vascularization mechanisms have not been fully elucidated.
The purpose of the present review is to organize in a critical way the information available regarding the role of endoglin in the different phenomena associated with post-ischemic revascularization and the cellular and molecular mechanisms involved in these phenomena.
Vascularization events Vessel organization
Capillaries and small vessels are the major protagonists of angiogenesis. The vascular wall in these vessels is composed of the vascular endothelium and mural cells. The vascular endothelium is a cell monolayer that lines all blood-contacting surfaces in the circulatory system. Its strategic location allows the endothelium to detect changes in oxygen and nutrient availability, blood flow, shear stress or arterial pressure and to initiate vascular processes in response to these changes. Thus, following several stimuli, the endothelium produces a wide variety of mediators that communicate events inside the vessel lumen to mural cells [7] .
The term mural cell refers generally to VSMCs and pericytes, both of which are involved in the formation of normal vasculature and are responsive to VEGF [29] . Pericytes are embedded in the basement membrane of the smallest blood vessels, where they communicate with ECs by means of both direct physical contact and paracrine signaling and are responsible for vessel stabilization and maturation [30] .
Hypoxia as the main angiogenic stimulus: HIF-1a and VEGF as principal mediators Impairment of the blood supply to an organ leads to the generation of a hypoxic microenvironment because the oxygen supply is lower than the oxygen demand of this organ. In the hypoxic microenvironment, the cellular response to low oxygen bioavailability involves the accumulation of the hypoxia-inducible transcription factor 1 (HIF-1). Under normoxic conditions, the cytoplasmic HIF-1 alpha subunit (HIF-1a) is ubiquitinated by the Von HippelLindau factor (pVHL) ubiquitin-ligase domain and subsequently degraded in the proteasome. HIF-1a has an oxygendependent degradation domain (ODD), which is hydroxylated by enzymes that are directly dependent on O 2 as a cofactor. The decreased O 2 bioavailability during hypoxia blocks HIF-1a hydroxylation and thus pVHL binding to HIF-1a, which will no longer be degraded in the proteasome. Thus, HIF-1a accumulates in the cytosol, translocates into the nucleus and binds to the HIF-1b subunit to form the active transcription factor [31] (Fig. 1a) . This transcription factor induces VEGF gene expression, a potent pro-angiogenic cytokine that induces EC differentiation, triggering the sprouting of ECs to form new vessels (Fig. 1b) . The VEGF gene has a hypoxia response element (HRE) within its promoter and an enhancer sequence to which HIF-1 binds once inside the nucleus and induces VEGF expression after hypoxia [32, 33] . Thus, HIF-1 belongs to the transcriptional complex that regulates hypoxia-induced VEGF expression, together with other transcription factors identified described later [34] .
Fibroblast growth factors (FGFs), particularly FGF1 and FGF2, are also potent pro-angiogenic factors. FGFs stimulate new blood vessel formation by driving EC proliferation and migration and also promoting extracellular matrix degradation and pericyte recruitment [35] . Both FGF and VEGF families act synergistically to promote neovascularization because FGF2 upregulates the expression of VEGFR and VEGF in ECs. VEGF upregulates the expression of FGF2. Moreover, FGF2 requires VEGFR1 to exert its capacity of enhancing EC organization [36] .
Sprouting and anastomosis
In response to angiogenic stimuli, ECs change their phenotype and bud to form a branch sprout in a process called sprouting. Vessel exposure to pro-angiogenic signals such as VEGF leads to the acquisition by a fraction of ECs of the commonly known tip cell phenotype, which is characterized by the formation of specialized structures, such as filopodia with migratory capacity, and is responsible for sprout guidance. Neighboring cells remain attached to this tip cell and undergo proliferation behind it to form a stalk, in a precisely regulated molecular process in which the Notch/Dll4 pathway plays a prominent role. Stalk cells are also responsible for forming a lumen connected to the lumen of the parent vessel [37] [38] [39] [40] . Growth of the sprout toward the stimulus requires EC migration, invasiveness and proliferation. Tip cells respond to a gradient of chemokines, mainly VEGF-A, which determine its migration direction (Fig. 2a) . It is unclear whether tip cells migrate before stalk cell proliferation and formation of the tube, or whether stalk cell proliferation pushes the tip cells forward [37] . Sprouting also requires the local degradation and new synthesis of the surrounding basement membrane, mediated by matrix metalloproteinases such as the MT1-MMP family. ECs themselves mediate extracellular matrix (ECM) cleavage, which entails soluble factor release, during the angiogenic response [3] .
Endothelial progenitor cells (EPCs) differentiated from hemangioblasts (multipotent precursor cells that can differentiate into both hematopoietic and ECs) were believed to be involved only in vasculogenesis, and embryonic mesodermal cells in situ differentiate into angioblasts that form the primary capillary plexus of the embryo. However, they also play a role in vascularization in the adult [41, 42] by both generating a sprout on their own-'postnatal or adult vasculogenesis'-and stimulating mature ECs to Fig. 1 Hypoxia is the main angiogenic stimulus. a High levels of HIF-1 accumulated in hypoxia due to the lack of its degradation stimulate the expression of genes with a hypoxia response element (HRE) in their promoters, such as VEGF, TGF-b or endoglin.
Adapted from Lee et al. [31] and Gray et al. [34] . b The hypoxic environment stimulates HIF-1 accumulation and the subsequent generation of a VEGF gradient between hypoxic tissue and nearby vessels where VEGF stimulates sprouting and new vessel growth Fig. 2 Overview of the mechanism of angiogenesis and arteriogenesis. a VEGF signaling through VEGF receptor type 2 (VEGFR-2) induces endothelial cell differentiation into a ''tip'' phenotype. Tip cells modulate the function of contiguous ''stalk'' by a mechanism mediated by the Notch-Dll4 and other signaling pathways. In the presence of high levels of membrane endoglin, tip cells degrade the ECM and migrate toward the hypoxic focus guided by the VEGF gradient, whereas stalk cells follow tip cells and proliferate, generating the early new vessel. Adapted from Blanco and Gerhardt [39] and Larrivee et al. [40] . b Shear stress triggers several endothelial processes during arteriogenesis, including EC release of NO and MCP-1, which mediate vasodilation and recruitment of mononuclear cells, respectively, together with endothelial quiescence and the recruitment of mural cells. Adapted from Carmeliet [7] , van Varik et al. [9] and Deindl et al. [68] undergo sprouting [37, 43] . The involvement of EPCs in neovascularization has been shown to be essential for ischemic disease recovery or in vascularization after stroke [44] [45] [46] .
After sprout elongation toward the angiogenic stimulus, tip cells can meet other tip cells belonging to other sprouts of different origin. Anastomosis of both sprouts leads to the formation of an entire new capillary that can undergo maturation [47, 48] .
Endothelial cells drive and mural cells polish angiogenesis
Mural cells have been demonstrated to be essential for angiogenesis, the structural integrity of the microvasculature and blood flow regulation, as they contribute to the formation of mature capillaries and pre-capillary arterioles. The interaction and interplay between ECs and mural cells play a pivotal role in vascular biology, including the control of lumen and tube formation, neovessel stability and the migration, proliferation, differentiation and survival of both cell types. In this regard, the recruitment of pericytes and VSMCs along the endothelial tube networks represents a critical event controlling capillary remodeling, maturation and stabilization [49] (Fig. 2b) . Furthermore, mural cell and EC co-assembly leads to vascular basement membrane deposition and tube stabilization in 3D matrices [50] .
Several adhesion receptors and signaling pathways have been reported to be involved in the interaction between ECs and mural cells. Growing vascular sprouts generate a concentration gradient of platelet-derived growth factor-B (PDGF-B). High levels of PDGF-B produced by tip cells promote the recruitment of mural cells expressing the PDGF receptor-b (PDGFR-b), stabilizing the growing vessels [37, 51] . In addition, co-cultured VSMCs enhance EC adhesion through activation of paxillin and ERK [52] . Moreover, pericyte-EC interactions depend on numerous direct contacts such as peg-socket contacts and adhesion plaques, which involve vascular endothelial cadherin (VEcadherin) trafficking [53] .
Mural and endothelial cells express several members of the integrin adhesion family of proteins, which are involved in the cell-cell and cell-matrix adhesion processes required for angiogenesis and vessel maturation [54] . A multiprotein complex involving integrin a v b 8 regulates vascular stability, angiogenesis and EC proliferation in the developing embryo [55] . In addition, b 1 integrin family members, including the fibronectin receptor a 5 b 1 , are major determinants of the mural cell phenotype, controlling mural cell adhesion and spreading and blood vessel wall stability [56] . Interestingly, integrins can be activated by pro-angiogenic chemokines such as CXCL12, triggering EC and leukocyte spreading and migration in an integrin-dependent manner [27, 57-59].
Moreover, CXCL12, which is upregulated by hypoxia [60] , increases PDGF-B expression by ECs and promotes the differentiation and recruitment of pericytes and vascular remodeling [61] , as well as myogenic differentiation [62] . Furthermore, CXCL12-induced expression of PDGF-B is in turn a potent activator of integrins [63] . However, despite the emerging relevant role of integrins as cell adhesion receptors in vascular biology [64] [65] [66] , their involvement in the interaction between ECs and mural cells remains largely unexplored.
Vascular remodeling
Vascular remodeling is an active process of structural alterations and arrangement of blood vessels that involves cell differentiation, proliferation, migration, death and ECM production. As described above, vascular remodeling after artery occlusion is a major process involved in organ reperfusion and includes at least two different processes that are often confused with one another: collateral growth and arteriogenesis.
Collateral growth is a vessel remodeling process with major importance for the restoration of organ perfusion after an arterial occlusion. It consists of the remodeling of preexisting arterio-arterial anastomosis with a very low flow to produce high capacity conductance arteries that provide most of the needs of the ischemic tissue for oxygen and nutrients. These arteries enlarge after femoral occlusion, and it is widely accepted that the number of preexisting collaterals does not increase after arterial occlusion, not even after maximal stimulation by increased shear stress [2] . Moreover, some authors postulate that collaterals can provide sufficient blood flow to substantially diminish ischemic tissue injury after sudden arterial obstruction [67, 68] and that post-ischemic reperfusion can be achieved without any other associated processes such as angiogenesis or arteriogenesis [69] .
However, long-term ischemia produces necrosis and vascular network regression. Consequently, even if blood flow is restored by collateral growth, a new expanded vascular network is required for the appropriate delivery of blood to all cells of these tissues. This phenomenon, which is also called neovascularization, is often considered synonymous with angiogenesis, but it involves much more extensive sequences of temporally controlled vascular processes, beginning with angiogenesis and the ensuing formation of a new, larger functional circulatory network. During this process, neovessels remodel via vascular cell differentiation and incorporation of perivascular cells into the newly formed vessel walls, resulting in the appropriate density and distribution of arterioles, venules and capillaries. Finally, the new vascular network matures and remodels into a more efficient perfusion circuit that meets the tissue perfusion needs and functions. This process of transformation from a capillary into a mature artery is called arteriogenesis, and this is the term that we will use in this review. It should be noted that the term arteriogenesis is also used by many researchers to describe collateral growth [69] .
The mechanisms and signals for mural cell recruitment to newly formed vessels have been described in a previous section. However, vascular wall development is dependent on other mechanisms that are common to arteriogenesis and collateral growth. The major inducer of this process is shear stress. In the first scenario, transmural pressure-induced stretch secondary to intravascular blood pressure contributes to vessel wall muscularization in arteriogenesis [70] . Moreover, it has been demonstrated that collateral growth is stimulated not by ischemia but by deformation of the endothelial cells through increased pulsatile fluid shear stress (FSS) caused by the pressure gradient created between the high pressure in pre-occlusive regions and the low pressure in post-occlusive areas connected by these collaterals [6, 71] . ECs exposed to prolonged laminar shear stress undergo configurational changes in surface adhesion receptors (including selectins and integrins). These changes result in cytoskeletal remodeling and subsequent activation of signal transduction pathways, ultimately leading to an anti-apoptotic state and increased release of the vasodilator NO by activation and expression of all NOS isoforms (eNOS, iNOS and nNOS) [72, 73] . NO plays a major role in stimulating arteriogenesis, as its inhibition markedly reduces the effects of increased FSS, whereas all NOS isoforms are significantly upregulated both at the transcriptional and at the translational level [73] . Deletion of both eNOS and iNOS leads to complete loss of collateral vessel remodeling upon femoral arterial occlusion [74, 75] . Moreover, increased shear stress mediates endothelium quiescence by inhibiting EC proliferation and promotes pericyte recruitment [76] . Elevations in shear stress also lead to the production of MCP-1 in the endothelium and the smooth muscle layer, which leads to a cascade inflammatory response with infiltrating leukocyte populations. MCP-1 attracts monocytes and T cells into the vessels during remodeling, a process that is favored by the marked increase in the expression of adhesion molecules on the endothelial surface of growing vessels. The monocytes that have accumulated into the collateral walls transform into macrophages, and resident macrophages become also activated. Mononuclear and activated VSMCs produce proteases and growth factors to digest the extracellular scaffold, allowing VSMC motility and providing space for the new cells. In addition to its participation in the digestion of the extracellular scaffold, monocytes produce paracrine growth factors necessary for the regeneration of arterial tissue [77] (Fig. 2b) . The major role of monocytes in arteriogenesis has been demonstrated by many experimental approaches, showing that the administration of MCP-1 or other substances favoring monocyte recruitment, or overtransfusion with monocytes, markedly stimulated collateral growth, whereas reduction of the blood monocyte count or deletion of the genes for MCP-1 or for the MCP-1 receptor (CCR2) was associated with markedly reduced collateral growth [2] .
In addition to monocytes, other leukocytes also contribute to arteriogenesis, mainly T lymphocytes and NK cells [78, 79] . Furthermore, EPCs have also been reported to be recruited by growing vessels, changing their phenotype into ECs or VSMCs [80, 81] .
ECs play also an important role in mural cell recruitment, but their role has been described in a previous section (endothelial cells drive and mural cells polish angiogenesis) (Figure 2b ).
A key role of endoglin in angiogenesis and vascular remodeling
What is endoglin?
Endoglin (Eng, CD105) is a type I homodimeric membrane glycoprotein that acts as an auxiliary receptor in the receptor complex for several members of the TGF-b family of cytokines. The TGF-b family comprises not only TGF-b isoforms but also bone morphogenetic proteins (BMPs), activins, inhibins, growth and differentiation factors (GDFs), among others. Endoglin interacts with type I and type II TGF-b receptors (TbRI and TbRII, respectively) to form the signaling TGF-b receptor complex [82] . Endoglin is highly involved in endothelium function and vascular homeostasis; it plays a major role in angiogenesis [83] .
The predominant full-length endoglin isoform, L-endoglin, is formed by two 90-kDa monomers that are linked to one another by disulfide bonds (Figure 3) . Structurally, the extracellular region of endoglin contains two distinct domains: (1) a zona pellucida (ZP) juxtamembrane domain that in human endoglin displays the prototypic Arg-GlyAsp (RGD) motif involved in integrin-based interactions [84, 85] , which has a mouse homologous sequence, TDD [27]; and (2) the NH 2 -terminal orphan domain involved in binding to BMP9, another member of the TGF-b family [85] [86] [87] . In addition to having a single transmembrane region, endoglin has a constitutively phosphorylated short intracellular domain, in which a PDZ binding domain plays a relevant role [84, 88, 89] . In human and mouse endoglin genes, the last intron can be retained as a result of an alternative splicing event. This intron retention leads to the generation of a premature stop codon in the endoglin mRNA, which is translated into a shorter protein named S-endoglin [90, 91] (Figure 3 ). In humans, S-endoglin has an intracellular domain that is 33 residues shorter than L-endoglin and lacks the PDZ binding motif ( Figure 3) . One of the splicing factors involved in this intron retention process is serine-arginine splicing factor 1 (SRSF1 or ASF/ SF2) [92] . Notably, ASF/SF2 is also involved in the selection of the splice site that yields pro-angiogenic VEGF isoforms, a process that is inhibited by TGF-b [90, 93] . Interestingly, S-endoglin expression is induced during senescence in ECs [92] [93] [94] and macrophages [95] . It is interesting that post-ischemic reperfusion is impaired in senescent individuals [67] . Different cell properties observed upon L-endoglin or S-endoglin expression suggest that the intracellular domain is essential for the modulation of several cellular processes [94, 96] . Notably, it can be postulated that there should be no differences in those events that are mediated or promoted by the extracellular domain of endoglin between isoforms because this domain is identical in both protein variants. Unless stated otherwise in this review, the reported endoglin data correspond to the predominant isoform L-endoglin.
A soluble form of endoglin, sEng, is released upon metalloprotease cleavage of any of the membrane isoforms [97, 98] . Increased sEng shedding has been reported to play a role in vascular pathologies such as pulmonary hypertension and preeclampsia [99, 100] and in several cancers [101] . The involvement of sEng in modulating angiogenic processes has also been suggested, i.e., impaired neovascularization in preeclampsia [102] . Moreover, sEng has been shown to inhibit capillary tube formation in vitro and to induce vascular leakage in vivo [103] . More recently, sEng has been demonstrated to impair angiogenesis in vivo [86] . Among the mechanisms of action proposed for sEng is sequestering of angiogenic ligands such as TGF-b or BMPs, or blocking the binding of fulllength endoglin to the receptor complex. As a result, TGFb family members cannot properly bind their receptors or transduce their angiogenic signal.
Evidence for the role of endoglin in angiogenesis and vascular remodeling

Endoglin is upregulated in tissues undergoing angiogenesis
Endoglin is mainly expressed in endothelium, where its gene promoter displays elevated activity compared with the other cell types [104] . Endoglin expression is a stronger marker of ECs than other markers such as VEGFR2, adhesion molecules (ICAM, PECAM, VCAM) or Von Willebrand factor (vWF) [105] . In addition to endothelium, endoglin is highly expressed in placental syncytiotrophoblasts [106] and, at lower levels, in activated blood monocytes [107] , VSMCs [108] , pericytes [109] and other different tissues, as previously reviewed [14] . Endoglin expression is upregulated in active endothelium undergoing angiogenesis. Specifically, endoglin expression increases in endothelium at the angiogenic edge, where vessel sprouting occurs [17] . Tissue immunostaining in different studies has revealed that several solid tumors and leukemic bone marrow undergoing active angiogenesis present strong labeling for endoglin in the endothelium of tumor vessels [15, [110] [111] [112] and weaker staining in non-malignant tissues. This increased expression of endoglin in the tumor endothelium correlates with a higher expression level of cellular proliferation markers [113] . Membrane-bound endoglin levels are elevated after myocardial infarction, and the correct neovascularization and recovery of the infarcted zone depends on adequate endoglin expression [20] . Moreover, endoglin is also highly expressed in blood vessels upon vascular injury in humans and mice [114] , after oxygen-induced angiogenesis in the retina [17, 18] and during pathological angiogenesis in chronic colitis [115] .
In vitro studies have shown that human umbilical vein endothelial cells (HUVECs) with low levels of endoglin are mainly quiescent, whereas HUVECs with upregulated endoglin expression are actively proliferating cells [110] .
Endoglin expression modifies angiogenesis and vascular remodeling
Endoglin null mice die around mid-gestation (E10-11.5) from defective yolk sac vasculogenesis and heart growth [116, 117] . The TGF-b1 and TGF-b receptors ALK1 and TbRII null mice also die around mid-gestation (E10-13.5) from similar vascular alterations, which involve not only the endothelium but also a reduction of VSMC numbers and recruitment to the vasculature plexus in the yolk sac and embryo [118] [119] [120] .
Hereditary hemorrhagic telangiectasia type 1 (HHT1), also known as Rendu-Osler-Weber syndrome, is a vascular disease caused by mutations in the endoglin gene that leads to endoglin haploinsufficiency. It is characterized by an impaired angiogenic process that leads to arteriovenous malformations (AVMs), fragile vessel walls, and pulmonary, liver and cerebrovascular problems due to vascular defects [121, 122] . Endoglin itself is responsible for endothelium integrity because an induced lack of endoglin leads to the apparition of AVMs when a pro-angiogenic or an inflammatory stimulus occurs in mice with endothelialspecific loss of endoglin (Eng-iKO e ) [123, 124] . Moreover, recent evidence has demonstrated that endoglin deficiency inhibits shear fluid stress blockage of EC proliferation together with pericyte recruitment [76] .
Endoglin heterozygous (Eng ?/-) mice-which have endoglin protein levels that are reduced by 50%-are usually used as an animal model to study HHT1 [125] . These haploinsufficient mice display delayed reperfusion and impaired angiogenesis following hindlimb ischemia induced by femoral ligation [19] . Moreover, the tumor growth rate and tumor capillary density are reduced in Eng ?/-compared with wild-type mice [21] . Furthermore, Jerkic et al. [19] demonstrated that mouse aortic endothelial cells (MAECs) from these mice showed reduced VEGF production and decreased proliferation and migration rates, which are essential processes for sprouting and initial steps of angiogenesis. Another study showed that Eng ?/-mice display impaired revascularization after myocardial infarction [20] . In addition, Eng ?/-mice develop smaller collateral arteries in response to shear stress after hindlimb ischemia, whereas the angiogenic response to ischemiarelated hypoxia generates larger but dysplastic capillaries in these mice. These two effects explain the delayed blood flow recovery after induction of hindlimb ischemia [22] .
Retinal neovascularization in Eng
?/-mice after oxygeninduced ischemic retinopathy (OIR) revealed markedly impaired angiogenesis in the retina, with little or no angiogenic tuft formation [18] . However, a larger number of proliferative cells have been reported within the vasculature of normal retinas from Eng ?/-mice at different stages of development, as compared with wild-type mice. It has also been reported that retinas from Eng ?/-pups under normal conditions show enhanced branching during sprouting [126] , suggesting that increased proliferation does not always lead to increased effective angiogenesis.
In vitro studies of the effect of different levels of endoglin in EC proliferation have produced discordant results. Some studies have reported that a lack of endoglin increases the proliferative response of ECs in culture [127] [128] [129] . Moreover, treatment with endoglin antisense oligonucleotides leads to reduced protein levels and an enhanced anti-proliferative response to TGF-b [130] . At variance with these results, cultured Eng ?/-ECs present smaller growth rates than Eng ?/? ECs [19, 131] , suggesting a pro-proliferative effect of endoglin. Moreover, an opposite endoglin-mediated cell responses to TGF-b, such as Smad activation and proliferative and migratory activities, has also been reported in different biological settings [12, 83, [131] [132] [133] [134] [135] . The different results observed among these reports can be explained by the distinct cell types (established EC lines, primary cultures of ECs, ECs from veins or arteries, ECs from micro-or macrovascular endothelium), cell differentiation stages (from embryos or adults) and experimental conditions (different media and variable TGF-b concentrations) used in every study. For example, experimental evidence supports the ability of endoglin to modulate TGF-b1 signaling in endothelium and, subsequently, angiogenesis. TGF-b1 has been largely considered to have an anti-proliferative effect over ECs [136] , while a dose-dependent effect of TGF-b1 in angiogenesis and cell proliferation has also been described in several reports [137] [138] [139] . When endoglin expression is blocked in HUVECs, in vitro EC tube formation upon TGF-b1 stimulation is impaired [130] . By contrast, other studies have suggested that endoglin counteracts TGF-b1-induced inhibition of angiogenesis-related responses in vitro. Thus, endoglin has been considered to promote EC proliferation in several studies. Furthermore, endoglin counteracts the inhibition of EC proliferation caused by high doses of TGF-b, while it promotes proliferation induced by low doses of TGF-b. This pro-proliferative effect of endoglin appears to be mediated by the TGF-b/ ALK1/ALK5 signaling pathway, whereas the loss of endoglin leads to TGF-b signaling through the ALK5 pathway, which has an anti-proliferative effect because ALK5 knockdown rescues EC proliferation in the absence of endoglin [139] . In a rat myoblast model, TGF-b showed an anti-proliferative effect at both low and high doses, and the effect at lower doses was rescued by overexpression of endoglin [138] . Conversely, low doses of TGF-b have shown an endoglin-mediated anti-proliferative effect in ECs isolated from the retina, as this effect was abrogated in ECs from Eng ?/-retinas [18] . These divergent results could again be explained based on the different types of cells used and their different origins. This conclusion prompts the necessity for further studies to elucidate the physiological role of TGF-b in EC proliferation and angiogenesis, as well as the function of endoglin in modulating this process.
Moreover, BMPs, which belong to TGF-b cytokine family, are also involved in the regulation of angiogenesis. BMP2, BMP4, BMP6 and BMP7 have been reported to increase VEGF levels, to enhance capillary tube formation, to promote the proliferation and migration of ECs during the activation phase of angiogenesis and to regulate the physiology of mural cells during the maturation phase [140, 141] . In contrast, anti-angiogenic responses have also been reported in other studies, again depending on the BMP dose and cellular context [142, 143] . Contradictory results regarding BMP9 and BMP10 in angiogenesis have also been described. Although an anti-angiogenic effect of BMP9 was first described [144] [145] [146] , it has been accepted that it occurs as a consequence of high BMP9 doses, while lower doses promote angiogenesis via ALK1 signaling [147, 148] . Additionally, endoglin interacts with BMP2 and BMP7 when other members of the receptor complex are present, and it can bind to BMP9 on its own [86, 87, 149] . Thus, endoglin may play a role in BMP signaling during angiogenesis. In support of this view, endoglin is necessary for BMP9 signaling in ECs involved in angiogenesis [150] , and the blockade of BMP9 binding to ALK1 prevents endoglin binding to ALK1 and the subsequent angiogenic response [148] .
Therefore, based on the current literature, endoglin appears to be an essential modulator of the cellular response to TGF-b and BMP cytokines. Moreover, its potential therapeutic implications have recently been reviewed by Jonker [151] .
How does endoglin orchestrate reperfusion?
Although it is widely recognized that endoglin is needed for proper reperfusion responses, the questions of where and how endoglin function to coordinate these complex responses remain to be answered. In this review, we intend to provide evidence of the involvement of endoglin in several angiogenic processes, which may help us understand why endoglin is crucial for accurate reperfusion. A summary of this evidence is listed in Table 1 .
Endoglin is involved in the response to hypoxia
Both TGF-b1 and endoglin genes can be regulated by hypoxia due to the presence of HREs in their gene promoters [152] (Figure 4 ). HREs are composite regulatory elements comprising a conserved HIF-binding sequence and a highly variable flanking sequence that modulates the transcriptional response. Thus, endoglin expression is upregulated under hypoxia conditions in human ECs, monocytic cell lines and epithelial cells [83, 152] . Furthermore, TGF-b1 itself increases endoglin expression [104, 132, [152] [153] [154] [155] [156] . These results suggest that gene expression of endoglin can be regulated by a synergistic cooperation between hypoxia and TGF-b1 due to the presence of HREs and Smad binding motifs in its gene promoter region.
In addition, TGF-b1 treatment further increases HIF-1a expression in endothelial cells under both hypoxic and normoxic conditions. TGF-b1 does not increase HIF-1a mRNA levels or decrease the rate of protein degradation, suggesting that it enhances normoxic HIF-1a translation [157] . However, hypoxia can also induce endoglin expression via other mechanisms, including MAP kinase pathway activation [158] . It should be noted that in the presence of both hypoxia and TGF-b, endoglin is able to prevent EC apoptotic death [154] . VEGF, a major angiogenic factor, is also induced by hypoxia, as its gene also have an HRE. There is an interrelationship between endoglin, VEGF and FGF because VEGF itself induces endoglin expression, and FGFR2 and FGF induces VEGF expression (Figure 4) . Angiogenesis (2017) 20:1-24 9
As described above, reduced retinal neovascularization has recently been reported in Eng ?/-mice after OIR due to an impaired angiogenic response of ECs [18] . However, endoglin can function as a protective factor against endothelial apoptosis because endoglin inhibition enhances hypoxia and TGF-b-induced endothelial apoptosis [154] . Therefore, the expression of endoglin increases after hypoxia, and endoglin seems to be essential to modulate angiogenesis in response to this hypoxic environment.
Endoglin modulates the production of angiogenic soluble factors VEGF and NO are two main endothelial factors that are directly involved in angiogenesis and vascular remodeling. Effects of reduced levels of endoglin Delayed reperfusion and altered vascularization following hindlimb ischemia [19, 22] Reduced tumor growth rate and tumor capillary density [21] Impaired revascularization after myocardial infarction [20] Defects in vessel maturation and mural cell recruitment [28, 83, 116, 224] Reduced VEGF production by macrovascular ECs [19] Increased VEGF production by microvascular ECs or angiogenic tissue [18, 187] Reduced EC proliferation and/or migration rates [19, 138, 162, 183, 184] Increased EC proliferation and/or migration rates [127] [128] [129] Impaired EC sprouting in response to VEGF [166] Increased endothelial permeability and/or metastasis [16, 18, 187, 188] Altered EPC differentiation and recruitment [162, [182] [183] [184] Circumstances associated with increased endoglin expression Cardiac and vascular injury [20, 114] Oxygen-induced angiogenesis in the normal retina [17, 18] Pathological angiogenesis in chronic colitis [115] Tumor vascularization [15, 16, 111, 113] There are several lines of experimental evidence, indicating that NO is a key component of the functional regulation of VEGF in the endothelium. NO mediates VEGF-induced HUVEC proliferation and tube organization of ECs in 3D culture. Moreover, EC exposure to VEGF increases both the endothelial NO synthase (eNOS) levels and NO production, whereas inhibitors of eNOS reduce VEGF-induced angiogenesis [159] . Furthermore, NO production is directly regulated by oxygen tension and is impaired under hypoxic conditions, and, in turn, NO induces HIF-1a degradation [160] . Interestingly, both NO and VEGF have been related to the function of endoglin. Our group has previously demonstrated that endoglin haploinsufficiency impairs NO production [161] due to reduced eNOS expression [19] . These results have been confirmed more recently in ECs from Eng ?/-mouse retina [18] . Furthermore, eNOS expression is upregulated by endoglin via Smad2 signaling [162] . More recently, reduced levels of eNOS have been described in EPCs from HHT patients [163] . Both endoglin and eNOS proteins colocalize and interact with one another within caveolae. Endoglin increases eNOS stability and is necessary for eNOS binding to its cofactor Hsp90. Therefore, eNOS is uncoupled in Eng ?/-cells and leads to increased ROS release and decreased NO production [164] . Like eNOS, Cav-1 and Hsp90, which can associate with endoglin, are located on the cytosolic side of plasma membrane, and it could be argued that their interaction with endoglin occurs through its intracellular domain. Consequently, this cytoplasmic interaction can be predicted to be altered or even abrogated in the case of the minor S-endoglin isoform.
A link between endoglin expression and VEGF-induced angiogenesis has been reported, although the underlying mechanisms have not been fully elucidated. Aortic ECs isolated from Eng ?/-mice produce less VEGF than control cells [19] , whereas retinal ECs isolated from these haploinsufficient mice produce larger amounts of VEGF [18] . These differences can be explained by the different origin of the ECs: macro-versus microvasculature. Moreover, HHT1 patients with mutations in the endoglin gene and vascular defects present increased VEGF plasma levels [165, 166] . BMP9 has been shown to enhance endoglin expression together with the blockade of VEGF-induced angiogenesis ex vivo [145] . Conversely, it has been shown that endoglin is required for VEGF-induced angiogenesis, although endoglin deficiency does not affect VEGF signaling [167] . However, anti-VEGF treatment in pancreatic carcinoma induces an increase in HIF-1a and in endoglin expression [168] . Moreover, endoglin and VEGF may be involved in endothelium stability, as will be discussed below.
In summary, endoglin, NO and VEGF, all of which have pro-angiogenic activity, are in equilibrium because their levels are mutually regulated and their mechanisms of action are interconnected. Further studies are required to fully understand the relationship among endoglin, NO and VEGF.
Endoglin in the recruitment and differentiation of endothelial progenitors
Populations of bone marrow-derived EPCs are present in the adult and are mobilized into the circulation by stimuli such as estrogen and VEGF [169] . Two populations have been differentially characterized from circulating endothelial precursors. On the one hand, early EPCs exhibit a hematopoietic profile, with a genomic fingerprint that resembles monocytes. On the other hand, blood outgrowth endothelial cells (BOECs) also known as endothelial colony-forming cells (ECPCs) are considered late EPCs and present an endothelial-like genomic profile. BOECs have been grown in vitro in several works to study angiogenesis because they possess the ability to form angiogenic sprouts in vitro [170] [171] [172] [173] . Moreover, a fraction of ECs within the vascular wall are the so-called resident precursor cells [174] . EPCs, both circulating and resident, can then differentiate into mature ECs that line the lumen of blood vessels and/or release growth factors that act in a paracrine manner to support the endothelium. EPCs are thus thought to function in angiogenesis and as a reservoir for the replacement of dysfunctional or senescent ECs to maintain the existing vessel walls [175, 176] . In addition, the levels of circulating EPCs are increased after vascular insult and, in several diseases, related to post-injury regeneration of the vasculature [177] [178] [179] [180] .
Endoglin is considered to be expressed only by mature ECs [174, 181] , but it can be expressed by EPCs after VEGF-driven differentiation into ECs [182] . Investigations of vasculogenesis-or vascularization of the embryo-in Eng ?/-mice have revealed enhanced ectopic CD34 expression in embryo cardinal veins. Because CD34 is considered to be an arterial marker, this finding suggests a loss of vessel identity due to deficient precursor cell homing in mice that are heterozygous for endoglin [183] . Characterization of BOECs from HHT1 patients has revealed an altered morphology, a disorganized F-actin cytoskeleton, a decreased capacity to form capillary-like structures and, therefore, a reduced angiogenic potential [184] . BOECs from HHT1 patients showed a downregulation of the expression of genes involved in angiogenesis, cell adhesion, cytoskeleton, migration, and cell cycle and survival, such as WASL, eNOS, PCDH12 (VE-cadherin 2), PECAM-1, ANGPT-2, CCNB2 (cyclin B2) and CDC25B (cell division cycle 25B). In addition, these cells presented reduced adhesion, migration and proliferation [185] . Recently, a reduced ability of these circulating HHT1 cells to differentiate has been reported, revealing a reduced binding to lectin or acLDL, characteristics of mature ECs and an attenuated mobilization toward strong angiogenic stimuli such as VEGF or CXCL12 [163] . Taken together, these results suggest a compromised function of EPCs in angiogenesis in the presence of reduced cellular levels of endoglin.
Endoglin modulation of endothelial cell barrier integrity
VEGF is a major inducer of angiogenesis and increased vascular permeability, leading to increased vessel leakage [186, 187] . Interestingly, endoglin haploinsufficiency in Eng ?/-mice is associated with weakness of the endothelial barrier and with an increased metastatic rate when tumors are produced in these mice [16] . Such increased vascular permeability was also observed in the distal colon of Eng ?/-mice and was related to enhanced levels of VEGF [188] . Of note, high levels of VEGF production have also been observed in ECs isolated from Eng ?/-mouse retinas [18] . Recently, vascular permeability, measured by the passage of fluorescent dextran through EC monolayers, was shown to be increased in Eng -/-and Eng ?/-ECs compared with control ECs. This hyperpermeability of endoglin-deficient EC monolayers is associated with a decrease in VE-cadherin expression and constitutive activation of RhoA, and it was further increased by TGF-b1 or VEGF [189] . In this context, the potential involvement of VE-cadherin deserves further analysis.
VE-cadherin expression is related to a quiescent state of the endothelium, when stable cell-cell interactions or adherens junctions are firmly established. VE-cadherin not only exerts a structural function by joining cells through homotypic interactions, but also inhibits angiogenic responses such as VEGFR2 phosphorylation and signaling, thus blocking the VEGF proliferative signal in the endothelium [190] . Conversely, VEGF can induce VEcadherin internalization and subsequent disruption of cellcell interactions of ECs in a b-arrestin-dependent manner [191] , a process that can be modulated by endoglin due to its ability to interact with both VE-cadherin and b-arrestin, as well as the above-described involvement in some responses to VEGF. Furthermore, endoglin haploinsufficiency diminishes cell-cell junctions by downregulating VE-cadherin, as well as PECAM, b-catenin and ZO-1 expression. Interestingly, VE-cadherin improves TGF-b receptor complex assembly at cell-cell contacts by interacting with TbRII, TbRI (ALK1 and ALK5) and endoglin. Although the interaction between VE-cadherin and endoglin is not necessary for the formation of the TGF-b receptor complex, it may act as a modulator of membrane protein assembly and the downstream signal transduction [18] . The same authors also reported that TGF-b-induced Smad2/3 activation in endoglin-deficient ECs is more persistent than Smad1 phosphorylation, in agreement with a previous report [192] , due, at least in part, to the VEcadherin-related effect. Moreover, VE-cadherin null cells present a lack of TGF-b inhibition of proliferation [193] .
Endoglin regulation of focal adhesions during EC migration
Endoglin localizes at focal adhesions and regulates cell migration [194] due, at least in part, to its capacity to bind zyxin, a protein that is concentrated at these zones and along the actin cytoskeleton [195] . Moreover, the presence of endoglin promotes the change in localization of zyxinrelated protein 1 (ZRP-1) from focal adhesions to actin fibrillar structures, which participates in reshaping the actin cytoskeleton [196] . Therefore, a reduction or increase in endoglin levels can lead to alterations in cellular morphology and cell motility. Because of the cytoplasmic localization of zyxin and ZRP-1, the intracellular domain of endoglin emerges as a key modulator of cytoskeletal organization and cell migration.
In support of this view, BOECs from HHT1 patients exhibit an altered morphology together with F-actin cytoskeleton disorganization and reduced migration [184, 185] . More recently, studies of cultured EPCs from HHT1 patients revealed an impaired mobilization of these cells toward pro-angiogenic stimuli such as VEGF and CXCL12, as compared with cells from healthy donors [163] . Furthermore, endoglin neutralization with the monoclonal antibody TRC105 decreases HUVEC migration and capillary-like structure formation, most likely by inhibiting the BMP9-Smad1/5/8 signaling pathway [197] . In contrast, overexpression of endoglin in various non-endothelial cell types causes diminished migration rates [195] . Moreover, either L-endoglin or S-endoglin isoform overexpression in prostate cancer cells results in reduced migration [194] . This effect has been confirmed in endoglin null murine embryonic endothelial cells (MEECs), resulting in increased migration, whereas the rescue of endoglin expression reduced migration to rates similar to those of wild-type cells. This effect on EC migration is dependent on the phosphorylation of Ser 646 in endoglin by ALK5 [192, 198] .
Endoglin modulation of TGF-b signaling in angiogenesis
TGF-b1 initiates signaling in ECs first by ligand binding to TbRII, which triggers the recruitment of TbRI and either ALK5 or the predominantly endothelial ALK1. Both TbRI and TbRII dimerize prior to assembly into the TGF-b receptor complex, forming not only homodimers but also heterodimers. It is widely accepted that stimulation of the TbRII/ALK5 signaling complex subsequently activates the phosphorylation of Smad2/3. Once phosphorylated, Smad2/3 binds to Smad4, and this heteromeric complex translocates into the nucleus where it functions as a transcription factor, increasing the expression of the ECM components, PAI-1 and PDGF-B, among other genes, while inhibiting the proliferation and migration of ECs [199] (Figure 5 ) . In addition, there is another TGF-b signaling route that involves the TbRII/ALK1 complex to promote the phosphorylation of Smad1/5/8. In turn, phosphorylated Smad1/5/8 binds to Smad4 and the resulting complex, with pro-angiogenic transcriptional activity, and promotes endothelial proliferation and migration as well as ECM degradation. Furthermore, the Smad1/5/8 pathway negatively regulates the expression of PAI-1, an ALK5 target gene [120, 192, [200] [201] [202] [203] (Figure 5 ) . This dual and opposite effect of ALK1/ALK5 remains controversial. For example, TGF-b signaling inhibition decreases retinal perfusion and impairs endothelial barrier function in mice [204] , while other authors have reported a TGF-b-mediated inhibition of pro-angiogenic molecules [205] or a pro-angiogenic effect of TGF-b blockade [206] . Moreover, Smad1/5/8-mediated blockade of EC migration [207] , and the inhibition of tip cell differentiation-with a migratory phenotype-by BMP9 signaling through ALK1-Smad1/5/8 have been described [40] . We should take into account, as discussed above, that different TGF-b concentrations may exert opposite effects on ECs, further complicating the dissection of the precise effect of endoglin.
Endoglin binds to TbRI (ALK1 or ALK5) and TbRII through both its extracellular and cytosolic domains in a ligand-dependent manner, and the latter is phosphorylated by both type I and II TGF-b receptors [208] . The cytosolic domain of endoglin is phosphorylated at Ser 634 and Ser 635 residues by TbRII. Absence of the PDZ domain promotes this phosphorylation, suggesting that proteins that bind to the PDZ domain, usually scaffolding molecules, can interfere with endoglin phosphorylation when bound to its degradation. This pathway antagonizes the ALK5 and Smad2/3 route involved in endothelial quiescence, ECM deposition mediated by PAI-1 and other cytoquines and mural cell recruitment. Adapted from ten Dijke et al. [12] and Bernabeu et al. [131] PDZ domain. Moreover, ALK1 phosphorylates endoglin at Thr 640 and Thr 654 residues, but this process requires previous Ser 634 and Ser 635 endoglin phosphorylation. Neither Ser 635 nor the PDZ domain interferes with the interaction of endoglin interaction with TbRII, ALK1 or ALK5 receptors [89] . The cytosolic domain of endoglin is also phosphorylated by ALK5 in Ser 646 and Ser 649 , and the loss of this phosphorylation impairs ALK1-induced phosphorylation of endoglin, shedding light on the mechanism responsible for ALK5-dependent ALK1/endoglin signaling [198, 200] . Moreover, the absence of cytosolic Thr residues in an endoglin-mutant protein prevents endoglin modulation of ALK1-dependent responses, such as a reduced viability or loss of focal adhesion and adhesive capacity responses in HUVECs [89] . These studies suggest that it is not only the interaction of endoglin with the TGF-b receptor complex that modulates the effects of TGF-b but also the phosphorylation of its intracellular domain. The cytosolic domain of endoglin has been shown to interact with several anchoring proteins, including zyxin, ZRP1, barrestin or GIPC. These interactions modulate several processes that are involved in angiogenesis [196, 209, 210] . S-endoglin lacks the PDZ binding motif as well as the Ser 634 , Ser 635 , Ser 646 , Ser 649 , Thr 640 and Thr 654 residues that are susceptible to phosphorylation [88] (Fig. 3) . Thus, a differential effect between L-endoglin and S-endoglin is expected, at least in those processes involving the cytosolic domain.
The ability of endoglin to modulate TGF-b family signaling through the ALK1/Smad1/5/8 pathway and its therapeutic relevance has recently been reviewed [151, 211] . It has been proposed that endoglin collaborates with the ALK1 signaling pathway to stimulate the active phases of angiogenesis through Smad1/5/8 activity [192, 212] . However, endoglin deficiency in the endothelium has been shown to reduce the activation not only of Smad1/5 but also of Smad2/3, an effect that is likely due to the reduced levels of TbRII [18] .
Furthermore, endoglin is believed to promote ALK1-mediated signaling in the presence of BMPs. Both BMP9 and BMP10 have been proposed to have a redundant effect in adult endothelium, and both cytokines can bind to ALK1 with high affinity. Unlike TGF-b, BMP9 binds to the endoglin orphan domain by itself [87] . BMP9 signals through the endoglin/ALK1 complex ( Figure 5) , and anti-ALK1 antibodies prevent the formation of the BMP9/ ALK1/endoglin complexes and attenuate BMP9-dependent signaling and sprouting [148] . Additionally, endoglin appears to be necessary for BMP9 signaling through ALK1 in HUVECs, in which TGF-b is unable to activate Smad1/ 5/8 signaling on its own [150] . Similarly, contradictory findings regarding the effect of BMPs in angiogenesis have been reported. On the one hand, BMP9 signaling via the ALK1-Smad1/5/8 pathway may promote in vitro angiogenesis in human microvascular endothelial cells (HMVECs) and HUVECs. On the other hand, other authors have reported that BMP9, despite signaling via ALK1/endoglin activation, inhibits EC proliferation and migration, promoting the resolution phases of angiogenesis. This duality of the angiogenic effects of BMP9 has been thoroughly reviewed [142, 151] .
The vast majority of articles concerning the role of endoglin in TGF-b signaling have assessed L-endoglin. To date, the role of the S-endoglin isoform in TGF-b/BMP signaling in ECs and in angiogenesis has been poorly addressed. S-endoglin and L-endoglin differentially modulate the ALK5 and ALK1 signaling pathways [94, 96] , suggesting that they may contribute to the complex and dual role of TGF-b in angiogenesis. Transgenic mice that specifically overexpress human S-endoglin in the endothelium exhibit a deficient angiogenic phenotype that drives a significant delay in tumor growth [91] , similar to the effects observed in mice lacking L-endoglin [21, 213] . S-endoglin has been shown to promote TGF-b signaling through ALK5, the reporter activity of which is inhibited by TGF-b in response to L-endoglin expression [94] . Because endoglin is not able to bind to TGF-b by itself, requiring the presence of TbRII [138] , the effect of S-endoglin on the TGF-b signaling may be related to receptor complex sequestering in competition with the long isoform. However, due to the ability of the extracellular domain of endoglin to bind BMP9 on its own, both L-and S-endoglin are expected to bind similarly this ligand. Therefore, S-endoglin can sequester not only the complex but also the ligand in the case of BMP9. In this regard, the importance of the L-endoglin/S-endoglin ratio based on a competitive effect between both isoforms for binding to the receptor complex can be postulated. According to this model, overexpression of S-endoglin would decrease the number of L-L endoglin homodimers and increase the frequency of L-S heterodimers, thus changing TGF-b signaling from ALK1/Smad1/5/8 to ALK5/Smad2/3. Furthermore, while L-endoglin overexpression decreases collagen I and CTGF expression and increases cell proliferation, S-endoglin overexpression strongly enhances collagen I and CTGF expression and reduces proliferation in rat myoblasts [96] . Taken together these experiments suggest that in contrast to the pro-angiogenic role of L-endoglin, S-endoglin has an anti-angiogenic effect.
Apart from the canonical Smad signaling pathway, TGF-b family members modulate other pathways such as Src kinase, ERK1/2, JNK and p38 MAP kinases or the PI3K/Akt route. MAPK activation has been related to enhanced cell survival, migration and capillary network organization, together with disruption of endothelial stability and cell-cell interactions and, thus, vascular permeability [18, 214, 215] . Akt signaling has emerged as a key modulator of in vitro capillary formation by ECs. BMP9 activates PI3K in an endoglin-dependent manner through endoglin PDZ domains by anchoring to the scaffolding protein GIPC that binds PI3K. In turn, Akt activation protects ECs from apoptosis, enhancing sprouting [210] . By contrast, TGF-b shows the opposite effect, reducing Akt activation and therefore promoting apoptosis, in an endoglin-dependent manner. Therefore, deficient TGF-b signaling could explain recent results showing enhanced activation of Akt, ERK, JNK and p38 in Eng ?/-ECs [18] . Conversely, endoglin expression inhibits the ERK signaling pathway [128, 216] . Moreover, endoglinmediated TGF-b-induced ERK inactivation depends on the interaction between the cytosolic domain of endoglin and b-arrestin [209, 217] . These results further suggest that the cytosolic domain of endoglin is essential for proper signaling of the TGF-b family of cytokines.
Endoglin in vascular remodeling
As above described, some studies have examined the role of endoglin in blood flow recovery after tissue ischemia. We have reported impaired reperfusion and angiogenesis after femoral ligation in Eng ?/-compared with wild-type mice [19] . Seghers et al. performed a similar experiment a few years later, and they also studied the effect of femoral ischemia on Eng ?/-mice together with the assessment of collateral growth. Similar to our results, after induction of hindlimb ischemia by femoral artery ligation, Eng ?/-mice exhibited a significant delay in blood flow recovery in the ischemic hindlimb compared with control mice. The analysis of collateral artery size revealed significantly smaller collateral arteries in Eng ?/-mice. MEECs were cultured under conditions of flow to mimic shear stress in vitro, revealing a time-dependent increase in endoglin mRNA expression [22] . Collateral formation is a shear stress-induced process that is associated with an increase in endoglin expression. Because endoglin-deficient mice present impaired collateral growth, a role for endoglin in this process can be hypothesized. It has recently been demonstrated that activation of endoglin under shear stress mediates vascular quiescence by inhibiting EC proliferation and promoting pericyte recruitment [76] . This interpretation is in agreement with the observation that endoglin is expressed by both ECs and VSMCs, as well as by fibroblasts in the perivascular stroma of arteries [218] [219] [220] , all of which are involved in collateral growth. Interestingly, shear stress plays a role in the activation of ALK5/TGF-b signaling in the endothelium [221] .
It should be noted that collateral formation is not always associated with increased endoglin expression. For example, cerebral hypoxia triggers active remodeling of small vessels into larger ones, but surprisingly, hypoxia produces a marked reduction of endoglin expression in brain endothelial cells (BECs) within actively remodeling arterioles [222] , and these remodeling BECs display an angiogenic switch in b 1 integrins from a 6 to a 5 , which has been previously described in angiogenesis [223] . In in vitro experiments, TGF-b1 promotes the angiogenic switch of BEC b 1 integrins. Taken together, these data suggest that BECs in remodeling brain collaterals show reduced endoglin expression, thereby altering TGF-b1 signaling to promote an angiogenic switch in b 1 integrins, facilitating vascular remodeling and the formation of new arteries that increase the supply of blood to the ischemic areas [222] . These findings also suggest that the precise role of endoglin in vascular remodeling depends on the tissue in which the ischemia is produced.
Endoglin regulation of mural and mononuclear cell recruitment
Mural cell recruitment is a key process in both arteriogenesis and collateral growth. Endoglin is highly expressed by ECs during arteriogenic processes at the same time as mural cell recruitment to vessels [83] . Several lines of experimental evidence support the involvement of endoglin in mural cell recruitment to EC tubes. First, mice lacking endoglin (Eng -/-) die by gestational day 11.5 from defective vascular development, although the vasculogenesis process remains unaffected [116, 117, 125] . Interestingly, loss of endoglin in these Eng -/-mice causes poor vascular smooth muscle development and arrested vascular remodeling [116] . It has also been reported that in yolk sacs from endoglin KO mice, aSMA levels are remarkably low because of the failure of VSMCs to differentiate and associate with ECs, so that blood vessels remain fragile and become dilated [116, 224] . This process is compatible with the characterization of HHT1 by recurrent epistaxis and internal hemorrhage due to the presence of immature and leaky vessels [225] . These results demonstrate that endoglin is essential for angiogenesis and VSMC recruitment to vessels. Failure of the endothelium to undergo remodeling in Eng -/-mice following arrested VSMC development suggests that VSMCs play a key role in regulating endothelial organization and that it is involved in the pathogenesis of HHT1 [28] .
Integrins play a key role in angiogenesis and vessel remodeling and maturation [54] . Thus, in growing vessels, the basement membrane undergoes degradation and is replaced by a fibronectin-rich matrix that induces integrin expression in mural cells, specifically fibronectin receptors such as a 5 b 1 and a v b 3 . Both integrins are involved in endothelial and mural cell proliferation and sprouting [226] [227] [228] .
Integrins also play a major role in monocyte recruitment, a major step in vascular remodeling as previously described. Thus, leukocyte arrest is mediated by the activation of integrins to assume their extended, high-affinity conformation, resulting in the binding of endothelial ligands such as ICAM-1 or VCAM-1 [229] . Human endoglin displays the prototypic RGD motif involved in integrin-based interactions within its ZP juxtamembrane domain [84, 85] . In addition, a physical and functional interplay between endoglin and b 1 integrins has been reported [106, 195, 207, 230] . More recently, endothelial endoglin has been identified as a ligand for leukocyte integrins [27] .
In addition to its role in mononuclear cell recruitment, endoglin has also been involved in the regulation of its function. Thus, endoglin is upregulated in activated monocytes from healthy subjects [107] , and this activation is impaired in cells from HHT1 patients [231] . In these patients, the type of cells composing the mononuclear cell fraction is modified. Thus, whereas in healthy subjects the most predominant cell types are T lymphocytes, monocytes and macrophages, with lower proportions of NK cells, dendritic cells and EPCs, the proportion of NK and T lymphocytes in HHT patients was found to be markedly reduced, while the B lymphocyte and monocyte proportions were unaltered and the phagocytic activity of the monocytes was conserved [232] . It has also been reported that HHT1 patients have reduced mononuclear cell recruitment to damaged tissue, which could explain the impaired tissue and vascular repair observed in these patients [233, 234] . In Eng ?/-mice subjected to an experimental infarct, microvascularity within the infarct zone was strikingly lower than that in wild-type mice, which resulted in a greater deterioration in cardiac function [20] . Moreover, after distal middle cerebral artery occlusion, Eng ?/-mice showed larger infarct/atrophic volumes and fewer infiltrating macrophages than wild-type animals, suggesting that endoglin deficiency impairs brain injury recovery by impairing macrophage homing, delaying inflammation resolution and reducing angiogenesis [235] . Furthermore, in an experimental model of brain arteriovenous malformations in mice induced by local injection of the VEGF gene, it has been reported that, compared with control mice, Eng-deleted mice show fewer macrophages homed to the angiogenic area 2 weeks after angiogenic stimulation [236] . This phenomenon can be explained by the reduced homing of monocytes in the injured tissue in Eng-deficient mice, as previously reported in other models [20, 27, 235] . However, Eng ?/-animals showed more tissue macrophages at 8 weeks the stimulus, when arteriovenous malformations were already formed, resulting in persistent inflammation, which can be explained by an impaired clearance of Eng-deficient macrophages in the injured tissue (angiogenic region) [235, 236] .
Reduced infiltration of leukocytes in HHT1 patients and in Eng
?/-mice can be explained by their reduced endoglin levels and involvement of the endoglin-integrin interaction in leukocyte recruitment [27, 237] . However, the previously described effects do not seem to be due only to a decrease in the number of inflammatory cells in the infarct area. A study conducted by van Laake et al. [20] showed that mononuclear cell recruitment was similar in wild-type and Eng ?/-mice, but an impaired function of the lowendoglin mononuclear cells produced defects in vessel formation and heart function in Eng ?/-mice. This phenotype was rescued by the injection of mononuclear cells from healthy human donors but not by mononuclear cells from HHT1 patients. This result is in agreement with the reduction in monocyte function (including oxidative burst and phagocytosis) in HHT patients [238] and in mouse monocytes lacking endoglin [239] . Moreover, a different role for endoglin isoforms in the regulation of monocytemacrophage functions has been proposed because L-endoglin overexpression promotes a pro-inflammatory M1-like macrophage phenotype, whereas S-endoglin favors the expression of anti-inflammatory M2 macrophage markers [95] .
Endothelial endoglin may also interact with the integrins present in vascular mural cells. Because endothelial endoglin is a ligand for b 1 integrins and VSMCs express these integrins [56], we can hypothesize that these receptors are involved in the adhesion of mural cells to ECs. A first candidate is a 5 b 1 , a pro-angiogenic integrin that is required for hypoxia-induced angiogenesis [228] and that is upregulated during angiogenesis and remodeling [222, 223, 226] . Integrin a 5 b 1 specifically recognizes the RGD motif in extracellular matrix proteins and is expressed by VSMCs, regulating their adhesion and recruitment to blood vessels [56] . Co-immunoprecipitation of endoglin with the a 5 integrin subunit demonstrated that endoglin could bind to this integrin independently of the RGD motif [207] . These authors reported that endoglin inhibits b 1 integrin subunit lysosomal degradation, thus promoting fibronectin/integrin a 5 b 1 complex formation, which in turn induces endoglin/ALK1 complex formation and enhances TGF-b1 activation of the Smad1/5/8 pathway. Moreover, TGF-b1 activates a 5 b 1 signaling in an endoglin-dependent manner because endoglin interacts with integrin via its extracellular domain to form complexes that are internalized to induce focal adhesion kinase (FAK) activation. A very recent study from our laboratory has demonstrated a critical role for endoglin in integrin-mediated adhesion of mural cells to ECs [28] . We describe an enhanced adhesion between vascular ECs and mural cells by integrin activators, which is inhibited by the suppression of membrane endoglin or b 1 -integrin, as well as by the addition of antiintegrin a 5 b 1 antibody or a peptide containing the RGD motif. Analysis of the binding of adherent mural cells to cells in suspension expressing different endoglin mutants indicates that the endoglin RGD motif plays a major role in the adhesion process. Endoglin haploinsufficiency induces a pericyte-dependent increase in vascular permeability [28] , whereas another study reported that retina from Eng ?/-mice presents no differences from wild-type mice in terms of the abundance of NG2, a protein that is characteristic of pericytes and VSMCs [126] . Further investigations are needed to elucidate the physiological role of endoglin in mural cell recruitment.
ALK5 inhibition, together with VEGF stimuli, induces the expression of a 5 and b 3 integrins in ECs and promotes angiogenesis in vitro and in vivo [227] . Because both endoglin isoforms differentially regulate the ALK1/ALK5 balance, it is tempting to speculate whether they modulate integrin expression. In this sense, using a human promonocytic cell line, it has been shown that both L-endoglin and S-endoglin inhibit a 1 , b 2 , a M and a L integrin expression, as well as integrin-mediated cellular adhesion and monocytic adhesion to ECs [240] . It remains to be established whether each endoglin isoform drives a cell lineage-dependent regulation of integrin expression.
Endoglin is not only expressed in the endothelium but also in mural cells, although little is known about its role in these cells. It has been reported that secreted protein acidic and rich in cysteine (SPARC) promotes pericyte recruitment in vivo and pericyte migration in vitro by regulating the function of endoglin. SPARC prevents endoglin incorporation into focal complexes, thus promoting pericyte migration. In addition, in the presence of SPARC, endoglin does not bind to latent TGF-b/a m integrin complexes, whereas the absence of SPARC allows endoglin to recruit TGF-b receptor components to latent TGF-b/a m integrin complexes. This process promotes ALK5/Smad2 signaling, which, in turn, blocks pericyte migration and recruitment [109] . Mesoangioblasts (MABs) are vesselassociated stem cells that express pericyte markers and improve skeletal muscle regeneration. Recently, the Smad1/5/8 pathway has been shown to be involved in MAB myogenic differentiation, but there are still no clues for the potential role of endoglin in this process [241] .
Conclusions and perspectives
Blood vessel formation and remodeling are essential processes in the maintenance of tissue homeostasis and function, and therefore, their alteration causes a variety of pathologic conditions. Endoglin, a TGF-b family co-receptor that is expressed mainly in endothelium, plays a key role in angiogenesis and blood vessel homeostasis, becoming a potential therapeutic target for pro-and antiangiogenic approaches for the treatment of diseases such as cancer, diabetes complications or post-ischemic disease. Endoglin expression is increased in the active endothelium, and it has been related to several endothelial processes involved in angiogenesis and vessel remodeling such as EC proliferation and migration, ECM production, leukocyte extravasation or endothelial interactions with mural cells.
TRC105 monoclonal antibody against endoglin acts as an anticancer drug that reduces tumor angiogenesis and is already used for the treatment of many solid tumors with satisfactory results. However, apart from this application, the endoglin facet as a therapeutic target for angiogenesis modulation has not been further exploited, due, at least in part, to the lack of knowledge regarding the precise role of endoglin during angiogenesis.
Unpublished studies from our laboratory reveal that post-ischemic angiogenesis is not improved in transgenic mice overexpressing the main isoform of endoglin (Nuñez-Gomez, Pericacho, Ollauri-Ibañez and Lopez-Novoa unpublished observations). It should be noted that, under normal conditions, endoglin expression is increased in response to ischemia, and thus, it is likely that the endoglin present in the vessels of ischemic tissues in wild-type mice is sufficient for producing the maximal angiogenic response and that endoglin does not improve the process. However, an excess of full-length exogenous endoglin could be useful in situations in which revascularization is reduced, as observed in patients with advanced age, hypercholesterolemia or diabetes [242] . It should be noted that under these conditions, NO production, a critical mediator of angiogenesis and revascularization, is reduced, and lower levels of endoglin are associated with lower NO production [19, 161, 243] , thus providing additional support for the hypothesis that endoglin is reduced in these diseases and that the administration of vectors containing endoglin could improve post-ischemic angiogenesis in these situations.
Finally, better knowledge of the mechanisms by which endoglin regulates post-ischemic vascularization could allow the development of effective therapies for diseases in which these phenomena are impaired. 
